Reports for APOTEX INC
Company Name APOTEX INC |
||
---|---|---|
Totals |
||
Shortage reports |
3367 |
|
Actual shortage: | 219 (7%) | |
Anticipated shortage: | 0 (0%) | |
Avoided shortage: | 10 (0%) | |
Resolved: | 3138 (93%) | |
Discontinuation Reports |
365 |
|
To be discontinued: | 24 (7%) | |
Discontinued: | 341 (93%) | |
Reversed: | 0 (0%) | |
Late reports |
144 (4%) |
|
Overdue reports |
68 (28%) |
Shortage reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-TADALAFIL | 10MG | TABLET | Resolved | 2019-03-20 | 2019-04-26 | 79051 |
APO-TADALAFIL | 10MG | TABLET | Resolved | 2019-07-03 | 2020-02-03 | 88368 |
APO-TADALAFIL | 20MG | TABLET | Resolved | 2019-07-17 | 2020-01-10 | 89551 |
APO-TADALAFIL | 5MG | TABLET | Resolved | 2019-08-23 | 2020-01-22 | 92387 |
APO-TADALAFIL | 10MG | TABLET | Resolved | 2020-03-04 | 2020-04-07 | 107717 |
APO-TADALAFIL | 5MG | TABLET | Resolved | 2020-10-28 | 2021-01-26 | 127376 |
APO-TADALAFIL | 5MG | TABLET | Resolved | 2018-04-02 | 2018-05-15 | 44520 |
APO-TADALAFIL | 2.5MG | TABLET | Resolved | 2024-01-05 | 2024-03-08 | 215227 |
APO-TADALAFIL | 10MG | TABLET | Resolved | 2024-01-05 | 2024-03-08 | 215239 |
APO-TADALAFIL | 5MG | TABLET | Resolved | 2024-01-05 | 2024-01-26 | 215242 |
APO-TADALAFIL | 5MG | TABLET | Resolved | 2024-03-08 | 2024-05-03 | 221705 |
APO-TADALAFIL | 2.5MG | TABLET | Resolved | 2024-04-19 | 2024-05-31 | 225773 |
APO-TADALAFIL | 10MG | TABLET | Resolved | 2024-04-19 | 2024-05-10 | 225790 |
APO-TADALAFIL | 5MG | TABLET | Resolved | 2023-08-04 | 2023-09-07 | 201165 |
APO-TADALAFIL | 5MG | TABLET | Resolved | 2023-10-27 | 2023-11-24 | 208373 |
APO-TADALAFIL | 10MG | TABLET | Resolved | 2023-10-27 | 2023-11-24 | 208403 |
APO-TADALAFIL PAH | 20MG | TABLET | Resolved | 2023-11-24 | 2023-12-22 | 211478 |
APO-TADALAFIL PAH | 20MG | TABLET | Resolved | 2022-02-18 | 2022-04-18 | 155321 |
APO-TADALAFIL PAH | 20MG | TABLET | Resolved | 2024-04-19 | 2024-05-03 | 225785 |
APO-TADALAFIL PAH | 20MG | TABLET | Resolved | 2020-02-05 | 2020-06-02 | 105356 |
Discontinuation reports
Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
---|---|---|---|---|---|---|
APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |